DrugPatentWatch Database Preview
Drugs in Development Information for SCY-078
» See Plans and Pricing
What is the development status for investigational drug SCY-078?
SCY-078 is an investigational drug.
There have been 13 clinical trials for SCY-078.
The most recent clinical trial was a Phase 2 trial, which was initiated on April 1st 2017.
The most common disease conditions in clinical trials are Candidiasis, Candidiasis, Vulvovaginal, and Mycoses. The leading clinical trial sponsors are Scynexis, Inc., Clinical Network Services (CNS) Pty Ltd, and Inncelerex.
There is one US patent protecting this investigational drug and nine international patents.
Summary for SCY-078
| US Patents | 1 |
| International Patents | 9 |
| US Patent Applications | 4 |
| WIPO Patent Applications | 5 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2017-04-01) |
| Vendors | 5 |
Recent Clinical Trials for SCY-078
| Title | Sponsor | Phase |
|---|---|---|
| ADME Study of [14C]-Ibrexafungerp in Healthy Male Subjects | Inncelerex | Phase 1 |
| ADME Study of [14C]-Ibrexafungerp in Healthy Male Subjects | Scynexis, Inc. | Phase 1 |
| Study to Evaluate the Effect of SCY-078 (Ibrexafungerp) on the PK of Pravastatin in Healthy Subjects | Clinical Network Services (CNS) Pty Ltd | Phase 1 |
Clinical Trial Summary for SCY-078
Top disease conditions for SCY-078
Top clinical trial sponsors for SCY-078
US Patents for SCY-078
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| SCY-078 | Start Trial | Antifungal agents | Merck Sharp & Dohme Corp. (Rahway, NC) Seynexis, Inc. (Research Triangle Park, NC) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for SCY-078
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| SCY-078 | Australia | 2009282474 | 2028-08-12 | Start Trial |
| SCY-078 | Canada | 2731941 | 2028-08-12 | Start Trial |
| SCY-078 | China | 102176827 | 2028-08-12 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
